Urgent need for pragmatic trial platforms in severe asthma

(eng) Asthma is a highly prevalent chronic disease of the airways affecting people of all ages. Worldwide, asthma causes significant morbidity, disability, and mortality. Most patients' mild-to-moderate asthma can be well controlled with inhaled corticosteroids, either as monotherapy or in combination with a second controller (eg, long-acting β 2-agonists [LABAs]). However, a subgroup of patients with severe asthma remain symptomatic and experience asthma exacerbations despite maintenance treatment with high-dose inhaled corticosteroids or LABAs […]